ANSWER: B

Rationale:

In the intact striatum, dopamine normally suppresses the tonically active cholinergic interneurons, maintaining a balance between dopaminergic and cholinergic signaling on medium spiny neurons. When nigrostriatal dopamine is depleted in PD, this suppression is lost and cholinergic interneuron activity increases, producing a relative cholinergic excess that contributes to motor dysfunction. Anticholinergic agents — primarily muscarinic M1 receptor antagonists — correct this imbalance by directly blocking the excess cholinergic signaling on striatal neurons, providing modest improvement in tremor. Option B correctly identifies this mechanism as muscarinic receptor blockade reducing the relative cholinergic excess from dopamine depletion, which is the pharmacological basis of anticholinergic efficacy in PD.

• Option A: Option A is incorrect; anticholinergics have no effect on tyrosine hydroxylase or dopamine synthesis.
• Option C: Option C is incorrect; MAO-B inhibition is the mechanism of selegiline and rasagiline, not anticholinergics.
• Option D: Option D is incorrect; direct D2 receptor stimulation is the mechanism of dopamine agonists such as pramipexole and ropinirole, not anticholinergics.
• Option E: Option E is incorrect; adenosine A2A receptor antagonism is the mechanism of istradefylline, a distinct adjunct agent covered later in this module.

ANSWER: D

Rationale:

Anticholinergic agents such as trihexyphenidyl occupy a narrow clinical niche in modern PD pharmacotherapy. Their primary role is tremor suppression in patients who are young (typically under 70 years), cognitively intact, free of contraindications such as benign prostatic hyperplasia (BPH) and narrow-angle glaucoma, and who have tremor-dominant PD that remains incompletely controlled on optimized dopaminergic therapy. Tremor in PD is characteristically resistant to levodopa at doses that adequately control bradykinesia and rigidity, and anticholinergics can provide incremental benefit in this specific situation. Option D correctly captures all of these criteria.

• Option A: Option A is incorrect; cognitive impairment of any degree, including PD dementia, is a contraindication to anticholinergic use because central muscarinic blockade markedly worsens cognition in patients with already-compromised cholinergic neurotransmission.
• Option B: Option B is incorrect; dyskinesia is the clinical problem addressed by amantadine extended-release (ER), not anticholinergics.
• Option C: Option C is incorrect; anticholinergics do not have a defined role in akinetic-rigid phenotypes and have no advantage in patients who have failed dopamine agonists on that basis.
• Option E: Option E is incorrect; off-time reduction is the indication for istradefylline and COMT or MAO-B inhibitors, not anticholinergics.

ANSWER: A

Rationale:

The peripheral adverse effects of anticholinergic drugs follow directly from muscarinic receptor blockade in peripheral organs. Blockade of M3 receptors on the detrusor muscle of the urinary bladder reduces detrusor contractility, impairing bladder emptying. In a patient with BPH who already has significant urethral outlet obstruction, the added loss of detrusor contractility from anticholinergic blockade can precipitate acute urinary retention — a urological emergency. BPH is therefore a strong contraindication to anticholinergic use, and anticholinergics should not be prescribed in this patient. Option A correctly identifies detrusor muscarinic blockade and its consequence of urinary retention as the hazard.

• Option B: Option B is incorrect; anticholinergics block cardiac muscarinic receptors and produce tachycardia, not bradycardia — the sinoatrial node is normally under parasympathetic restraint, and muscarinic blockade accelerates the heart rate.
• Option C: Option C is incorrect; anticholinergics do not constrict vascular smooth muscle via muscarinic blockade and do not cause hypertension by this mechanism.
• Option D: Option D is incorrect; muscarinic receptors in the renal tubule are not a clinically significant target of anticholinergic agents, and anticholinergics do not cause sodium retention through this mechanism.
• Option E: Option E is incorrect; adrenal chromaffin cells express nicotinic, not muscarinic, receptors, and anticholinergic agents at clinical doses do not increase catecholamine release through this pathway.

ANSWER: C

Rationale:

Narrow-angle glaucoma is an absolute contraindication to anticholinergic drugs. The mechanism is anatomical: anticholinergic-induced mydriasis (pupillary dilation from blockade of the iris sphincter muscle) causes the peripheral iris to fold against the trabecular meshwork in eyes with a shallow anterior chamber angle, physically obstructing aqueous humor drainage. This precipitates acute angle-closure crisis — a rapid rise in intraocular pressure that causes severe ocular pain, nausea, halos around lights, and can lead to irreversible optic nerve damage within hours if untreated. In any patient with Parkinson's disease and a history of narrow-angle glaucoma, anticholinergic agents are absolutely contraindicated. Option C correctly describes this mechanism.

• Option A: Option A is incorrect; macular degeneration is a disease of photoreceptor and retinal pigment epithelium degeneration that is not caused or worsened by the mild dry-eye effect of anticholinergics, and it is not a contraindication.
• Option B: Option B is incorrect; diabetic retinopathy involves microvascular disease of the retina and is not a contraindication to anticholinergics on the basis of autonomic effects on intraocular vessels.
• Option D: Option D is incorrect and reverses the pathophysiology; open-angle glaucoma involves impaired drainage through a structurally open angle and is not caused by aqueous humor overproduction from muscarinic stimulation — furthermore, open-angle glaucoma is not an absolute contraindication to anticholinergics in the way narrow-angle glaucoma is.
• Option E: Option E is incorrect; central retinal artery occlusion is a vascular event unrelated to the mechanism of anticholinergic ophthalmic toxicity.

ANSWER: E

Rationale:

Parkinson's disease itself impairs cortical and hippocampal cholinergic neurotransmission as a consequence of neurodegeneration beyond the nigrostriatal system; this is why PD carries a high risk of cognitive impairment and dementia. When anticholinergic agents such as trihexyphenidyl are added in this setting, central muscarinic blockade further suppresses already-compromised cholinergic signaling in the cortex and hippocampus, producing a dose-dependent spectrum of central adverse effects: cognitive blunting and word-finding difficulty at lower doses, vivid hallucinations and paranoid ideation at moderate doses, and frank anticholinergic delirium at toxic doses. In a patient with pre-existing MCI, even doses that were previously tolerated can become cognitively intolerable as underlying neurodegeneration progresses. This is why any degree of cognitive impairment, including MCI, is a contraindication to anticholinergic use in PD. Option E correctly identifies central muscarinic blockade in a patient with reduced cholinergic reserve as the explanation.

• Option A: Option A is incorrect; levodopa-induced psychosis is a recognized complication of PD pharmacotherapy, but the clinical timeline and the presence of pre-existing MCI point to anticholinergic central toxicity as the cause in this case.
• Option B: Option B is incorrect; while progressive PD dementia can cause hallucinations, the temporal relationship between long-term anticholinergic use in a cognitively impaired patient and the onset of these symptoms implicates the anticholinergic, not coincidental disease progression.
• Option C: Option C is incorrect; there is no recognized delayed peripheral cholinergic rebound syndrome with anticholinergics — the central adverse effects described here are a direct pharmacodynamic consequence of ongoing central muscarinic blockade, not a rebound phenomenon.
• Option D: Option D is incorrect; istradefylline is not being taken by this patient, and its adverse effect profile, while including hallucinations, operates through a distinct mechanism unrelated to the clinical scenario presented.

ANSWER: B

Rationale:

Anticholinergics should never be discontinued abruptly after prolonged use. Patients on long-term anticholinergic therapy can experience a withdrawal syndrome upon abrupt discontinuation that includes nausea, sweating, and anxiety, in addition to rebound worsening of parkinsonian tremor. The correct approach is a slow taper over weeks to months, reducing the dose by approximately 25–50% every two to four weeks. During the taper, the patient should be monitored for tremor worsening; if tremor worsens significantly, consideration should be given to bridging with an alternative agent such as propranolol or clonazepam before completing the discontinuation. Option B correctly describes this gradual tapering approach with appropriate monitoring.

• Option A: Option A is incorrect; there is no inflammatory mechanism in anticholinergic withdrawal, and corticosteroids have no role in managing this process.
• Option C: Option C is incorrect; switching to benztropine does not constitute a taper and does not leverage a pharmacokinetic self-taper effect — benztropine is also an anticholinergic and must itself be tapered when discontinued; the underlying problem of anticholinergic dependence is not resolved by switching agents.
• Option D: Option D is incorrect; abrupt discontinuation is hazardous, and doubling levodopa carries its own risks including worsening dyskinesia and hallucinations without reliably suppressing tremor rebound.
• Option E: Option E is incorrect; indefinite maintenance at a low dose solely to avoid the discomfort of tapering is not a recommended strategy when clear clinical indications for discontinuation exist, such as cognitive impairment and urinary symptoms.

ANSWER: D

Rationale:

Amantadine's antidyskinetic mechanism is uncompetitive, low-affinity antagonism at the N-methyl-D-aspartate (NMDA) receptor — a ligand-gated ion channel that mediates fast excitatory glutamatergic neurotransmission. In the basal ganglia of patients with levodopa-induced dyskinesia, pathologically elevated glutamatergic drive through NMDA receptors contributes to the aberrant corticostriatal plasticity that underlies dyskinesia. By reducing NMDA receptor-mediated glutamate signaling, amantadine ER attenuates this dyskinetic drive without blocking dopaminergic input. The drug also has modest dopaminergic actions (promoting dopamine release, inhibiting reuptake, and weak MAO inhibition), but the NMDA antagonist effect is the clinically dominant mechanism for dyskinesia reduction in advanced PD. Option D correctly identifies uncompetitive NMDA antagonism as this mechanism.

• Option A: Option A is incorrect; D1 receptor blockade would worsen parkinsonism by opposing the direct pathway, and amantadine does not have significant D1 antagonist activity relevant to dyskinesia management.
• Option B: Option B is incorrect; COMT inhibition is the mechanism of entacapone and tolcapone, which reduce wearing-off rather than dyskinesia; in fact, COMT inhibitors can worsen dyskinesia by increasing peak levodopa exposure.
• Option C: Option C is incorrect; muscarinic M1 blockade is the mechanism of anticholinergic agents such as trihexyphenidyl, which target tremor rather than dyskinesia.
• Option E: Option E is incorrect; adenosine A2A receptor blockade is the mechanism of istradefylline, which targets off-time reduction rather than dyskinesia.

ANSWER: A

Rationale:

Amantadine extended-release 137 mg (Gocovri) was approved by the FDA in 2017 specifically for the treatment of dyskinesia in patients with PD receiving levodopa-based regimens. This approval was significant because it represented the first time any pharmacological agent received an FDA indication explicitly for levodopa-induced dyskinesia — a complication that affects a substantial proportion of patients after years of levodopa therapy and that, before Gocovri, had been managed only with off-label strategies including immediate-release amantadine. The EASE LID and EASE LID 3 trials provided the clinical evidence base; in pooled analysis Gocovri produced an approximately 41% reduction in Unified Dyskinesia Rating Scale (UDysRS) scores from baseline versus approximately 14% with placebo — a placebo-subtracted difference of roughly 27% — with simultaneous reduction in off-time. Option A correctly states this indication and its significance as the first approved agent for this specific complication.

• Option B: Option B is incorrect; Gocovri is not approved for monotherapy in early PD and has no indication based on levodopa intolerance — its dyskinesia indication presupposes that the patient is already established on levodopa therapy.
• Option C: Option C is incorrect; Gocovri does not have a prevention indication for motor fluctuations in newly diagnosed patients, and such early use is not part of its approved labeling.
• Option D: Option D is incorrect; while Gocovri does reduce off-time as a secondary effect, its primary approved indication is dyskinesia management — characterizing it as an off-time agent reserved after failure of COMT and MAO-B inhibitors inverts the clinical priority and does not reflect the approved labeling.
• Option E: Option E is incorrect; anticholinergics, not amantadine ER, are the pharmacological approach to drug-induced parkinsonism, and Gocovri does not carry this indication.

ANSWER: C

Rationale:

The bedtime dosing strategy for Gocovri (amantadine ER 137 mg) is a deliberate pharmacokinetic design feature. The extended-release formulation produces a broad, sustained plasma concentration peak that occurs during the morning hours after an evening dose — approximately 7 to 12 hours after ingestion. This timing is clinically deliberate because levodopa-induced dyskinesia and off-periods are typically at their worst during the morning hours, when patients are waking from sleep and the overnight interval since their last levodopa dose has produced both dopamine fluctuation and dyskinesia vulnerability. By aligning peak amantadine plasma concentrations with the period of greatest dyskinesia burden, bedtime dosing of Gocovri maximizes the drug's antidyskinetic effect when it is most needed. Option C correctly identifies this pharmacokinetic rationale.

• Option A: Option A is incorrect; NMDA receptor circadian cycling during sleep is not the pharmacological basis of bedtime dosing — the rationale is entirely about timing peak plasma concentrations to the morning period of dyskinesia burden.
• Option B: Option B is incorrect; while hallucinations are an adverse effect of amantadine ER, the dosing strategy was not designed to conceal psychotomimetic effects during sleep — this option misrepresents the pharmacokinetic rationale as a safety workaround.
• Option D: Option D is incorrect; there is no clinically significant pharmacokinetic interaction between amantadine and levodopa that bedtime dosing is designed to avoid.
• Option E: Option E is incorrect; amantadine's extended-release matrix absorption is not driven by body temperature during sleep — this is a fabricated mechanism unrelated to the actual drug formulation design.

ANSWER: E

Rationale:

The EASE LID and EASE LID 3 trials evaluated amantadine ER 137 mg at bedtime against placebo in patients with PD and levodopa-induced dyskinesia. The primary efficacy outcome was reduction in UDysRS (Unified Dyskinesia Rating Scale) scores, which measure the severity and impact of dyskinesia. Gocovri produced approximately a 41% reduction in UDysRS scores from baseline versus approximately 14% with placebo — a placebo-subtracted difference of roughly 27% that was statistically significant and clinically meaningful. Importantly, amantadine ER also reduced daily off-time without worsening total on-time, meaning patients gained both better dyskinesia control and improved motor function during on-periods. This dual benefit — reducing dyskinesia while also modestly reducing off-time — distinguishes Gocovri from simple dose reduction of levodopa, which would reduce dyskinesia at the cost of increased off-time. Option E correctly summarizes these trial results.

• Option A: Option A is incorrect; while off-time reduction was a secondary benefit, the four-hour figure is a significant overstatement, and dyskinesia reduction was the primary finding and the basis of the approved indication.
• Option B: Option B is incorrect; the EASE LID trials reported group-mean reductions in UDysRS scores, not complete elimination rates or the specific proportions described — this framing misrepresents the trial results.
• Option C: Option C is incorrect; the EASE LID trials did not include a DBS comparator arm, and no pharmacological agent has been shown non-inferior to DBS for dyskinesia control in this way.
• Option D: Option D is incorrect; amantadine does not prolong levodopa's half-life and has no clinically meaningful effect on hepatic CYP enzymes — its antidyskinetic mechanism is NMDA receptor antagonism, not pharmacokinetic.

ANSWER: B

Rationale:

Amantadine is predominantly renally cleared, and dose adjustment is required when renal function is impaired to prevent drug accumulation and increased toxicity. For Gocovri (amantadine ER), the approved dosing adjustments are: creatinine clearance 30–59 mL/min — initial dose 68.5 mg once daily at bedtime, maximum 137 mg; creatinine clearance 15–29 mL/min — 68.5 mg once daily at bedtime as both initial and maximum dose; and end-stage renal disease (creatinine clearance below 15 mL/min) — contraindicated. This patient with a CrCl of 45 mL/min falls in the 30–59 mL/min range and therefore starts at the 68.5 mg dose. Option B correctly identifies this adjustment.

• Option A: Option A is incorrect; amantadine is not predominantly hepatically metabolized — it is renally eliminated, and accumulation in renal impairment is the basis for dose adjustment.
• Option C: Option C is incorrect; Gocovri is not contraindicated in all patients with CrCl below 60 mL/min — the 30–59 and 15–29 mL/min ranges both allow use at appropriately reduced doses, and only end-stage renal disease (CrCl below 15 mL/min) requires avoidance.
• Option D: Option D is incorrect; dose reduction begins once CrCl falls below 60 mL/min, not below 15 mL/min — deferring any adjustment until CrCl reaches 15 mL/min would expose the patient to drug accumulation and toxicity across the moderate and severe CKD ranges, and CrCl below 15 mL/min is the point of contraindication, not dose halving.
• Option E: Option E is incorrect; there is no recommendation to substitute immediate-release amantadine in CKD — the extended-release formulation's absorption kinetics are not rendered unpredictable by renal impairment, and the approved renal dosing guidance applies to Gocovri directly.

ANSWER: D

Rationale:

Livedo reticularis is a well-recognized and distinctive adverse effect of amantadine in both its immediate-release and extended-release forms. It presents as a mottled, net-like (reticular) purplish or bluish skin discoloration of the extremities, most commonly the lower legs, caused by cutaneous vasospasm affecting the small vessels of the skin. The appearance — sometimes described as looking like a fishnet or lace pattern — is characteristic and distinguishes it from other drug rashes. Despite its striking appearance, livedo reticularis from amantadine is benign; it does not indicate ischemia, vasculitis, or systemic disease, and it resolves with drug discontinuation. Patients should be informed about this potential adverse effect proactively so that they are not alarmed if it develops. Drug discontinuation is not required unless the patient finds it cosmetically unacceptable or other concerning features are present. Option D correctly identifies the finding, its mechanism, its reversibility, and the importance of proactive patient counseling.

• Option A: Option A is incorrect; amantadine-associated livedo reticularis is not caused by vasculitis and does not require dermatology referral — the finding is a known, benign adverse effect with a recognized mechanism of cutaneous vasospasm.
• Option B: Option B is incorrect; livedo reticularis is not edema and is not caused by sodium retention — the two conditions have entirely different appearances and mechanisms.
• Option C: Option C is incorrect; livedo reticularis occurs with both immediate-release and extended-release amantadine formulations and is not specific to the Gocovri polymer matrix.
• Option E: Option E is incorrect; livedo reticularis from amantadine is not caused by thrombocytopenia and does not indicate peripheral arterial occlusion — the finding is a vasospastic skin reaction, not a thrombotic vascular event.

ANSWER: A

Rationale:

Istradefylline operates through selective antagonism of the adenosine A2A receptor, which is expressed selectively on the striatopallidal medium spiny neurons of the indirect pathway. Under normal conditions, adenosine A2A receptor activation on these neurons opposes dopamine D2 receptor signaling, increasing striatopallidal neuron firing and amplifying the inhibitory output of the indirect pathway — a net effect that suppresses motor activation. In the dopamine-depleted striatum of PD, this A2A-mediated overactivation of the indirect pathway contributes to the akinesia and rigidity of the off state. By selectively blocking A2A receptors on striatopallidal neurons, istradefylline reduces their firing rate and decreases indirect pathway overactivity, facilitating motor output. Critically, this mechanism does not involve direct stimulation of dopamine receptors, making istradefylline mechanistically distinct from all dopaminergic adjuncts. Option A correctly identifies this mechanism.

• Option B: Option B is incorrect; istradefylline is an A2A receptor antagonist, not an A1 receptor antagonist — A1 and A2A receptors have distinct distributions and functions, and A1 receptor blockade is not istradefylline's mechanism.
• Option C: Option C is incorrect; istradefylline does not inhibit phosphodiesterase enzymes or directly increase cAMP concentrations — PDE4 inhibition is the mechanism of roflumilast and other agents in different drug classes.
• Option D: Option D is incorrect; istradefylline does not act on dopamine receptors of any subtype — its non-dopaminergic mechanism is central to its pharmacological identity.
• Option E: Option E is incorrect; istradefylline does not block AMPA receptors — AMPA and NMDA glutamate receptors are distinct ion channels, and AMPA receptor antagonism is not involved in istradefylline's mechanism.

ANSWER: C

Rationale:

The adenosine A2A receptor and the dopamine D2 receptor are co-expressed on the same striatopallidal medium spiny neurons and function as antagonistic modulators of these neurons. Adenosine A2A receptor activation opposes D2 receptor signaling — it increases intracellular cAMP and activates these striatopallidal neurons, increasing their inhibitory (GABAergic) output to the globus pallidus interna (GPi). This increased GPi output suppresses thalamic activity and reduces motor cortex activation, contributing to the akinesia and rigidity of the off state. In the dopamine-depleted striatum of PD, where D2 receptor signaling is insufficient to suppress these neurons, A2A receptor-mediated activation of the indirect pathway is pathologically amplified. Istradefylline's selective A2A receptor blockade reduces striatopallidal neuron firing and decreases the indirect pathway's inhibitory output on GPi, facilitating motor activation through the thalamocortical circuit. Option C correctly describes this mechanism.

• Option A: Option A is incorrect; A2A receptors are on indirect pathway (striatopallidal) neurons, not direct pathway neurons, and istradefylline targets off-time reduction, not dyskinesia.
• Option B: Option B is incorrect; A2A receptors on striatopallidal neurons do not regulate dopamine synthesis in nigrostriatal terminals — this describes a different neurobiological relationship entirely.
• Option D: Option D is incorrect; A2A receptor activation does not directly promote glutamate release from corticostriatal terminals — while glutamate and adenosine pathways interact in the striatum, istradefylline's mechanism is A2A receptor blockade on postsynaptic striatopallidal neurons, not presynaptic glutamate modulation.
• Option E: Option E is incorrect; A2A receptor activation does not increase acetylcholine release from striatal cholinergic interneurons in the manner described, and istradefylline's mechanism bears no pharmacological resemblance to anticholinergic drug action.

ANSWER: E

Rationale:

Istradefylline (Nourianz) was approved by the FDA in 2019 as an adjunct to levodopa/carbidopa in adults with Parkinson's disease who experience off episodes — the periods of reduced motor function that occur as levodopa's effect wanes between doses. Its approved dosing is 20 mg once daily, with uptitration to 40 mg once daily permitted if the lower dose is tolerated but additional benefit is needed. It is taken once daily at approximately the same time each day and has no food restrictions. Clinical trials demonstrated a reduction in daily off-time of approximately 0.9 hours per day versus placebo across the istradefylline trial program. Option E correctly states both the approved indication (adjunct for off episodes in levodopa-treated PD) and the standard dosing.

• Option A: Option A is incorrect; istradefylline is not approved for monotherapy in early PD — its indication presupposes that the patient is already receiving levodopa/carbidopa and is experiencing off episodes, and it has no approved use as first-line therapy before levodopa initiation.
• Option B: Option B is incorrect; istradefylline is not approved for levodopa-induced dyskinesia — that indication belongs to amantadine ER (Gocovri); istradefylline targets off-time, not dyskinesia, and is not dosed twice daily.
• Option C: Option C is incorrect; istradefylline does not have an indication for tremor management and is not a substitute for anticholinergic agents in cognitively impaired patients — tremor is addressed by anticholinergics or dopaminergic optimization, not by A2A receptor antagonism.
• Option D: Option D is incorrect; istradefylline does not carry a dyskinesia indication, and its approved dosing is not bedtime-specific as Gocovri's is — the bedtime dosing requirement is a pharmacokinetic feature specific to amantadine ER, not istradefylline.

ANSWER: B

Rationale:

Istradefylline is metabolized primarily by CYP1A1 and CYP3A4. Rifampin is one of the most potent known inducers of CYP3A4; co-administration dramatically increases CYP3A4 activity, accelerating istradefylline catabolism and substantially reducing its plasma concentrations — potentially to subtherapeutic levels. The prescribing information for istradefylline states that strong CYP3A4 inducers (including rifampin and carbamazepine) significantly reduce plasma concentrations and that the combination should be avoided. Separately, tobacco smoke contains polycyclic aromatic hydrocarbons that induce the CYP1A family of enzymes (CYP1A1 and CYP1A2) through the aryl hydrocarbon receptor pathway; because istradefylline is substantially metabolized by CYP1A1, heavy smoking increases its clearance, and the prescribing information recommends 40 mg once daily for patients who smoke 20 or more cigarettes per day. In a patient on rifampin who is also a smoker, both factors reduce istradefylline exposure, and the rifampin interaction is sufficiently severe to warrant avoiding co-administration entirely. Option B correctly identifies both interactions.

• Option A: Option A is incorrect and reverses rifampin's effect on CYP3A4 — rifampin is an inducer, not an inhibitor, and increases, not reduces, CYP3A4 activity, thereby lowering istradefylline levels rather than raising them.
• Option C: Option C is incorrect; rifampin does not inhibit COMT, and smoking does not cause pulmonary sequestration of istradefylline — these mechanisms are fabricated.
• Option D: Option D is incorrect; istradefylline is not renally eliminated and does not compete with rifampin for tubular secretion — the primary elimination pathway is hepatic CYP3A4 metabolism.
• Option E: Option E is incorrect; smoking's pharmacokinetic interaction with istradefylline is through induction of the CYP1A enzymes, not MAO-B upregulation, and rifampin has a well-characterized and clinically significant CYP3A4 induction interaction with istradefylline.

ANSWER: A

Rationale:

Istradefylline is metabolized in part by CYP3A4 (alongside CYP1A1), and its plasma concentrations are therefore sensitive to drugs that alter CYP3A4 activity. Carbamazepine is a classic strong CYP3A4 inducer: it upregulates CYP3A4 expression, accelerates istradefylline catabolism, and substantially reduces istradefylline plasma concentrations — potentially to subtherapeutic levels that would undermine off-time control. For this reason the prescribing information directs that concomitant use of istradefylline with strong CYP3A4 inducers (such as rifampin and carbamazepine) be avoided rather than managed by dose adjustment, because the magnitude of induction cannot be reliably overcome by uptitration. The appropriate management is to recognize the interaction and coordinate with the prescribing physician about an alternative anticonvulsant or an alternative off-time strategy, rather than simply continuing the combination. Option A correctly identifies carbamazepine as a strong CYP3A4 inducer that lowers istradefylline exposure and the label directive to avoid the combination.

• Option B: Option B is incorrect and reverses the direction of the interaction; carbamazepine is a CYP3A4 inducer, not an inhibitor, so it lowers rather than raises istradefylline concentrations, and a 10 mg istradefylline dose does not exist in the approved regimen.
• Option C: Option C is incorrect; istradefylline is eliminated by hepatic metabolism, not renal tubular secretion, and does not share a renal elimination pathway with carbamazepine, so competition for tubular secretion is not the mechanism.
• Option D: Option D is incorrect; istradefylline is extensively metabolized by cytochrome P450 enzymes (CYP1A1 and CYP3A4) and is not eliminated unchanged in the urine, so carbamazepine's enzyme induction is clinically relevant.
• Option E: Option E is incorrect; CYP3A4 induction by carbamazepine increases clearance and lowers istradefylline exposure rather than generating an accumulating active metabolite — istradefylline's identified metabolites each account for a small fraction of parent-drug exposure and do not drive toxicity through this pathway.

ANSWER: A

Rationale:

This case illustrates the critical concept of cumulative anticholinergic burden. Patients with PD are particularly vulnerable to anticholinergic cognitive toxicity because PD itself impairs cortical and hippocampal cholinergic neurotransmission as part of its neurodegenerative process. When a patient with PD is simultaneously prescribed multiple medications with anticholinergic properties — antiparkinson agents (benztropine), urologic agents (oxybutynin), and sedating antihistamines (diphenhydramine) — each with its own muscarinic blocking activity, the combined anticholinergic load can be sufficient to produce significant cognitive impairment even when no single agent is at a dose that would be expected to cause problems in isolation. Clinicians managing PD patients must assess the total anticholinergic load across all prescribed medications, not limit their attention to the specifically antiparkinson anticholinergic agent. Option A correctly identifies this principle.

• Option B: Option B is incorrect; the recommendation to switch from benztropine to trihexyphenidyl does not address the underlying problem of cumulative anticholinergic burden from three separate agents — substituting one anticholinergic for another does not reduce the total burden, and the clinical priority is to reduce the overall anticholinergic load, not to change which anticholinergic antiparkinson drug is used.
• Option C: Option C is incorrect; while diphenhydramine has high CNS penetrance and significant anticholinergic activity, attributing cognitive decline solely to one agent in a patient on three anticholinergic drugs misses the cumulative burden concept that is the central clinical lesson of this scenario.
• Option D: Option D is incorrect; oxybutynin, despite being described as having peripheral-predominant anticholinergic effects at standard doses, does have clinically significant CNS anticholinergic activity especially in older patients — there is no anticholinergic agent at standard clinical doses that can be assumed to be cognitively safe in an elderly patient with PD.
• Option E: Option E is incorrect; while progressive PD dementia is part of the differential, the temporal clustering of three anticholinergic agents with a worsening cognitive trajectory in a vulnerable patient makes drug-induced anticholinergic cognitive toxicity the priority diagnosis to address before attributing decline to disease progression.

ANSWER: C

Rationale:

The clinical distinction between amantadine ER (Gocovri) and istradefylline (Nourianz) is precisely the distinction between these two patients' primary problems. Amantadine ER holds the FDA indication specifically for levodopa-induced dyskinesia — the involuntary, often choreiform movements that occur during peak dopamine exposure in levodopa-treated patients. Patient A, whose dominant problem is dyskinesia limiting function during on-periods, is the target population for Gocovri. Istradefylline holds the FDA indication for off-episode reduction as an adjunct to levodopa/carbidopa — targeting the wearing-off phenomenon where motor function deteriorates as levodopa levels fall between doses. Patient B, whose dominant problem is wearing-off with significant daily off-time and no dyskinesia, is the target population for istradefylline. Option C correctly matches each patient to the mechanistically and clinically appropriate agent.

• Option A: Option A is incorrect and reverses the indications — istradefylline is an off-time drug, not a dyskinesia drug; amantadine ER's NMDA antagonism targets dyskinesia, not wearing-off as a primary mechanism.
• Option B: Option B is incorrect; while amantadine ER does modestly reduce off-time as a secondary effect, using it for Patient B, whose primary problem is wearing-off with no dyskinesia, would not be the most clinically appropriate primary choice — istradefylline has a specific indication for this presentation.
• Option D: Option D is incorrect; there is no established requirement to sequence istradefylline before amantadine ER for dyskinesia, and the claim that Patient B requires prior COMT inhibitor failure before receiving off-time treatment is not a guideline requirement — clinical decision-making is based on which agent best matches the primary problem.
• Option E: Option E is incorrect; dyskinesia and wearing-off, while both caused by levodopa-related dopamine fluctuations, are distinct pharmacodynamic phenomena occurring at different phases of the levodopa cycle and are targeted by different agents through different mechanisms.

ANSWER: E

Rationale:

Age over 70 years is listed as a relative but strong contraindication to anticholinergic therapy in PD across most treatment guidelines, and the reasons are multiple and compounding. First, aging itself is associated with progressive loss of cholinergic neurons in the basal forebrain, cerebral cortex, and hippocampus — independent of PD — reducing cholinergic reserve such that any additional muscarinic blockade is more likely to produce clinically significant cognitive impairment. Second, blood-brain barrier function becomes less restrictive with age, increasing CNS drug penetrance. Third, renal and hepatic drug clearance both decline with age, increasing steady-state plasma concentrations even at standard doses. Fourth, older patients are more likely to be on multiple medications with their own anticholinergic properties, compounding the cumulative anticholinergic burden. In PD, where the disease additionally depletes cortical cholinergic signaling, these age-related factors combine to make the central adverse effect risk disproportionately high in patients over 70. This patient, though cognitively intact, is at substantially elevated risk of developing anticholinergic-induced cognitive complications, and the age factor alone should prompt serious reconsideration of whether the modest tremor benefit justifies initiation. Option E correctly identifies age over 70 as a relative but strong contraindication and explains the mechanistic basis.

• Option A: Option A is incorrect; age independently increases anticholinergic CNS risk through multiple mechanisms beyond pre-existing cognitive impairment — the age risk is not mediated solely by baseline neurological disease.
• Option B: Option B is incorrect and reverses the pharmacokinetic reality — reduced renal clearance in older patients increases drug accumulation and raises, not lowers, the risk of adverse effects; tolerance to anticholinergic adverse effects does not develop in the manner described.
• Option C: Option C is incorrect; age over 70 is a relative contraindication, not an absolute disqualifier — while most guidelines strongly discourage use in this age group, the recommendation allows clinical judgment for exceptional cases; characterizing it as an automatic disqualification overstates the guideline position.
• Option D: Option D is incorrect; the central cognitive risk from anticholinergics is very much age-dependent, and age-related reduction in cholinergic reserve is a primary driver of that risk — the central risk cannot be separated from age on the basis of blood-brain barrier integrity alone.

ANSWER: B

Rationale:

Istradefylline is metabolized in part by CYP3A4, a hepatic enzyme whose activity is reduced in proportion to the degree of hepatic impairment. As hepatic function declines, istradefylline clearance decreases and plasma concentrations rise at any given dose. The approved dosing guidance for istradefylline specifies that patients with moderate hepatic impairment (Child-Pugh class B) should be limited to a maximum dose of 20 mg once daily, because uptitration to 40 mg may produce plasma concentrations that are associated with increased adverse effects including hallucinations and impulse control disorders. For patients with severe hepatic impairment (Child-Pugh class C), istradefylline is not recommended. Option B correctly states the dose cap of 20 mg in moderate hepatic impairment based on reduced hepatic metabolic capacity.

• Option A: Option A is incorrect; istradefylline is primarily hepatically metabolized via CYP3A4, not renally eliminated — hepatic impairment directly reduces clearance and dose adjustment is required.
• Option C: Option C is incorrect; uptitration to 40 mg is not permitted in moderate hepatic impairment under the approved prescribing information — 20 mg is the maximum dose for this patient population.
• Option D: Option D is incorrect; istradefylline is not contraindicated in all degrees of hepatic impairment — it may be used at a reduced maximum dose in moderate impairment (Child-Pugh class B); only severe impairment (Child-Pugh class C) warrants avoidance of the drug.
• Option E: Option E is incorrect; a 10 mg dose of istradefylline does not exist in the approved dosing regimen, and the transaminase monitoring threshold described is not part of the istradefylline prescribing information — this option fabricates both a dose and a monitoring protocol.

ANSWER: D

Rationale:

This question integrates the patient-selection principles from all three drug classes covered in this module. The key contraindication to apply here is the absolute contraindication to anticholinergic therapy in any patient with cognitive impairment, including mild cognitive impairment (MCI). In PD, where the disease itself depletes cortical cholinergic signaling, any added muscarinic blockade from anticholinergic agents carries a high risk of precipitating acute confusion, hallucinations, or worsening cognitive function — even at doses that would be tolerated in cognitively intact patients. Anticholinergics must not be used in this patient. For the patient's dominant problem of dyskinesia, amantadine ER (Gocovri) is the appropriate agent to consider: it holds the specific FDA indication for levodopa-induced dyskinesia and its mechanism (NMDA antagonism) does not contraindicate its use in MCI. However, amantadine ER can itself cause hallucinations and cognitive adverse effects, so monitoring is required in a patient with cognitive vulnerability. Option D correctly identifies the contraindication (anticholinergics) and the most appropriate adjunct (amantadine ER with monitoring).

• Option A: Option A is incorrect; NMDA antagonism by amantadine ER is not listed as a contraindication in patients with MCI, and amantadine ER holds the specific dyskinesia indication — istradefylline addresses off-time, not dyskinesia, and is not the indicated agent for this patient's primary problem.
• Option B: Option B is incorrect; istradefylline does not require a formal cognitive capacity assessment before prescribing, and the framing fabricates a regulatory barrier to prescribing.
• Option C: Option C is incorrect and dangerously inverts the correct contraindication — anticholinergics are contraindicated in patients with cognitive impairment, not the indicated class; claiming they retain safety in MCI directly contradicts the central safety message of this module.
• Option E: Option E is incorrect; amantadine ER and istradefylline are not contraindicated in MCI — both may be used with appropriate monitoring; levodopa dose reduction alone is not the only pharmacological strategy available and may worsen motor function unacceptably.